Natural products industry companies share overviews on the latest science on their branded ingredients and formulations to ...

By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.

Galcanezumab provided greater reductions in migraine frequency, resulting in a shift from chronic to episodic migraine over a 12-month period compared with placebo.

Magnesium and melatonin are commonly used as sleep aids, though their effects are generally modest. Learn how they work and ...

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to ...

The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next ...

An expert discusses how CheckMate 274 is a phase 3, randomized, double-blind trial evaluating adjuvant nivolumab vs placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after ...